The DOI matches its Crossref record; 103 of the 105 references it cites were found in a registry or an index.
From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors
Abstract
Members of the B cell lymphoma 2 (BCL-2) gene family have a central role in regulating programmed cell death by controlling pro-apoptotic and anti-apoptotic intracellular signals. In cancer, apoptosis evasion through dysregulation of specific BCL-2 family genes is a recurring event; accordingly, selective inhibition of specific anti-apoptotic BCL-2 family proteins represents an exciting therapeutic opportunity. A combination of nuclear magnetic resonance (NMR)-based screening and structure-based drug design has yielded the first bona fide BCL-2 homology 3 (BH3) mimetics, including the BCL-2 and BCL-X L dual antagonist navitoclax, which is the first BCL-2 family inhibitor to show efficacy in patients with cancer. Clinical experience with navitoclax prompted the generation of the highly selective BCL-2 inhibitor venetoclax, which is now approved in the United States for the treatment of patients with chronic lymphocytic leukaemia with 17p deletion who have received at least one prior therapy. Recent advances have also been made in the development of potent and selective inhibitors of BCL-X L and myeloid cell leukaemia 1 (MCL1), which are additional BCL-2 family members with established anti-apoptotic roles in cancer. Here we review the latest progress in direct and selective targeting of BCL-2 family proteins for cancer therapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Conversely, the BCL2 inhibitor venetoclax is currently available for the treatment of CLL patients who fail to obtain clinical benefit from conventional therapies [1046], and several other molecules with a similar mechanism of action are currently in clinical development [118] (source https://clinicaltrials.gov/).”
From Molecular mechanisms of cell death: recommendations of the nomenclature committee on cell death 2018. (2018) · cites this paper as [1046]
In the citing paper
“The use of Bcl-xl inhibitors as senolytics is largely limited by their on-target and dose-limiting platelet toxicity.”
From Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity (2020) · cites this paper as [24]
In the citing paper
“Bcl-xl inhibition with ABT263 and other small molecular inhibitors induces platelet apoptosis and results in severe thrombocytopenia, which prevents the use of ABT263 and other Bcl-xl specific inhibitors in the clinic—even for cancer patients—because platelets solely depend on Bcl-xl for survival24–27.”
From Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity (2020) · cites this paper as [24]
In the citing paper
“ABT263 (also known as navitoclax), a Bcl-2 and Bcl-xl dual inhibitor23,24, is one of the most potent and broad-spectrum senolytic agents identified to date16–18.”
From Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity (2020) · cites this paper as [24]
In the citing paper
“Because both SCs and platelets, but not NCs, are primarily dependent on Bcl-xl for survival16–18,24–27 (Supplementary Fig. 1h), we evaluated the effects of PZ compared with ABT263 on the viability of WI38 NCs (Fig. 1g, left panel), IR-SCs (Fig. 1g, middle panel), and platelets (Fig. 1g, right panel).”
From Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity (2020) · cites this paper as [24]
In the citing paper
“As reported, ABT263 was highly toxic to both WI38 IR-SCs (Fig. 1g, middle panel) and platelets16–18,24–27 (Fig. 1g, right panel; Supplementary Fig. 2).”
From Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity (2020) · cites this paper as [24]
In the citing paper
“Therefore, PZ can selectively induce apoptosis in SCs, but not platelets, which are dependent on Bcl-xl for survival while having minimal toxicity to NCs that are less sensitive to Bcl-xl inhibition than SCs16–18,24–27.”
From Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity (2020) · cites this paper as [24]
In the citing paper
“the BCL2 inhibitor venetoclax has been approved by regulatory agencies for use in patients with CLL or small lymphocytic lymphoma (SLL) (Ashkenazi et al., 2017)”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Ashkenazi et al., 2017
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Apoptosis: A Basic Biological Phenomenon with Wideranging Implications in Tissue Kinetics
Kerr, J. F. R., Wyllie, A. H., & Currie, A. R. (1972) · British Journal of Cancer · doi:10.1038/bjc.1972.33 · Cited by 15,673
Death Receptors: Signaling and Modulation
Ashkenazi, A., & Dixit, V. M. (1998) · Science · doi:10.1126/science.281.5381.1305 · Cited by 5,866
Self-citationDanial, N. N., & Korsmeyer, S. J. (2004) · Cell · doi:10.1016/s0092-8674(04)00046-7 · Cited by 4,651
The landscape of somatic copy-number alteration across human cancers
Beroukhim, R., Mermel, C. H., Porter, D., Wei, G., Raychaudhuri, S., Donovan, J., Barretina, J., Boehm, J. S., Dobson, J., Urashima, M., et al. (2010) · Nature · doi:10.1038/nature08822 · Cited by 4,017
An inhibitor of Bcl-2 family proteins induces regression of solid tumours
Oltersdorf, T., Elmore, S. W., Shoemaker, A. R., Armstrong, R. C., Augeri, D. J., Belli, B., Bruncko, M., Deckwerth, T. L., Dinges, J., Hajduk, P. J., et al. (2005) · Nature · doi:10.1038/nature03579 · Cited by 3,407
Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells
Vaux, D., Cory, S., & Adams, J. (1988) · Nature · doi:10.1038/335440a0 · Cited by 3,355
Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy
Czabotar, P. E., Lessene, G., Strasser, A., & Adams, J. M. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3722 · Cited by 3,219
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
Souers, A. J., Leverson, J. D., Boghaert, E. R., Ackler, S. L., Catron, N. D., Chen, J., Dayton, B. D., Ding, H., Enschede, S. H., Fairbrother, W. J., et al. (2013) · Nature Medicine · doi:10.1038/nm.3048 · Cited by 3,058
Self-citationDiscovering High-Affinity Ligands for Proteins: SAR by NMR
Shuker, S. B., Hajduk, P. J., Meadows, R. P., & Fesik, S. W. (1996) · Science · doi:10.1126/science.274.5292.1531 · Cited by 2,045
Flagged first, then by citations
2 of the 105 references couldn’t be matched to a known paper.
Research works printed but not linked: 1
- Seymour, J. F. et al. Reduction of tumor lysis syndrome (TLS) risk in chronic lymphocytic leukemia (CLL) patients treated with ABT-199 (GDC-0199): results of modifications to dosing schedule and TLS prophylaxis [abstract P868]. Haematologica 99 (Suppl. 1), 321 (2014).
Cited by
Sorted by citations
Galluzzi, L., Vitale, I., Aaronson, S. A., Abrams, J. M., Adam, D., Agostinis, P., Alnemri, E. S., Altucci, L., Amelio, I., Andrews, D. W., et al. (2018) · Cell Death & Differentiation · doi:10.1038/s41418-017-0012-4 · Cited by 6,680
Small molecules in targeted cancer therapy: advances, challenges, and future perspectives
Zhong, L., Li, Y., Xiong, L., Wang, W., Wu, M., Yuan, T., Yang, W. M., Tian, C., Miao, Z., Wang, T., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00572-w · Cited by 1,813
Mitochondrial metabolism and cancer
Porporato, P. E., Filigheddu, N., Pedro, J. M. B., Kroemer, G., & Galluzzi, L. (2017) · Cell Research · doi:10.1038/cr.2017.155 · Cited by 1,323
NINJ1 mediates plasma membrane rupture during lytic cell death
Kayagaki, N., Kornfeld, O. S., Lee, B. L., Stowe, I. B., O’Rourke, K., Li, Q., Sandoval, W., Yan, D., Kang, J., Xu, M., et al. (2021) · Nature · doi:10.1038/s41586-021-03218-7 · Cited by 857
A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity
Khan, S., Zhang, X., Lv, D., Zhang, Q., He, Y., Zhang, P., Liu, X., Thummuri, D., Yuan, Y., Wiegand, J. S., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0668-z · Cited by 688
MOMP, cell suicide as a BCL-2 family business
Kalkavan, H., & Green, D. R. (2017) · Cell Death and Differentiation · doi:10.1038/cdd.2017.179 · Cited by 707
The BCL-2 arbiters of apoptosis and their growing role as cancer targets
Adams, J. M., & Cory, S. (2018) · Cell Death & Differentiation · doi:10.1038/cdd.2017.161 · Cited by 530
Caenepeel, S., Brown, S. P., Belmontes, B., Moody, G., Keegan, K. S., Chui, D., Whittington, D. A., Huang, X., Poppe, L., Cheng, A. C., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0387 · Cited by 432
Targeted nanomedicine for cancer therapeutics: Towards precision medicine overcoming drug resistance
Bar-Zeev, M., Livney, Y. D., & Assaraf, Y. G. (2017) · Drug Resistance Updates · doi:10.1016/j.drup.2017.05.002 · Cited by 324
BH3-Mimetic Drugs: Blazing the Trail for New Cancer Medicines
Mérino, D., Kelly, G. L., Lessène, G., Wei, A. H., Roberts, A. W., & Strasser, A. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.11.004 · Cited by 300
PROTACs: great opportunities for academia and industry (an update from 2020 to 2021)
He, M., Cao, C., Ni, Z., Liu, Y., Song, P., Hao, S., He, Y., Sun, X., & Rao, Y. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00999-9 · Cited by 283
He, Y., Zhang, X., Chang, J., Kim, H.-N., Zhang, P., Wang, Y., Khan, S., Liu, X., Zhang, X., Lv, D., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15838-0 · Cited by 280
Moreau, P., Chanan-Khan, A. A., Roberts, A. W., Agarwal, A. B., Facon, T. T. F., Kumar, S. K., Touzeau, C., Punnoose, E. A., Cordero, J., Munasinghe, W. P., et al. (2017) · Blood · doi:10.1182/blood-2017-06-788323 · Cited by 273
Self-citationTargeting BCL-2 in B-cell malignancies and overcoming therapeutic resistance
Kapoor, I., Bodo, J., Hill, B. T., Hsi, E. D., & Almasan, A. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-03144-y · Cited by 255
The BCL-2 family of proteins and mitochondrial outer membrane permeabilisation
Birkinshaw, R. W., & Czabotar, P. E. (2017) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2017.04.001 · Cited by 229
Fleury, H., Malaquin, N., Tu, V., Gilbert, S., Martinez, A., Olivier, M.-A., Sauriol, S. A., Communal, L., Leclerc-Desaulniers, K., Carmona, E., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-10460-1 · Cited by 228
Applications of Bioisosteres in the Design of Biologically Active Compounds
Meanwell, N. A. (2023) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.3c00765 · Cited by 231
Immunomodulation by targeted anticancer agents
Petroni, G., Buqué, A., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2021) · Cancer Cell · doi:10.1016/j.ccell.2020.11.009 · Cited by 212
Sulfonamide derivatives as potential anti-cancer agents and their SARs elucidation
Wan, Y., Fang, G., Chen, H., Deng, X. M., & Tang, Z. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113837 · Cited by 208
Augmenting NK cell-based immunotherapy by targeting mitochondrial apoptosis
Pan, R. A., Ryan, J. A., Pan, D., Wucherpfennig, K. W., & Letai, A. G. (2022) · Cell · doi:10.1016/j.cell.2022.03.030 · Cited by 204
VDAC2 enables BAX to mediate apoptosis and limit tumor development
Chin, H. S., Li, M. X., Tan, I. K. L., Ninnis, R. L., Reljic, B., Scicluna, K., Dagley, L. F., Sandow, J. J., Kelly, G. L., Samson, A. L., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-07309-4 · Cited by 196
Mitochondrial quality control as a key determinant of cell survival
Sedlackova, L., & Korolchuk, V. I. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2018.12.012 · Cited by 187
Venetoclax for AML: changing the treatment paradigm
Pollyea, D. A., Amaya, M. L., Strati, P., & Konopleva, M. Y. (2019) · Blood Advances · doi:10.1182/bloodadvances.2019000937 · Cited by 172
Apoptosis: A mammalian cell bioprocessing perspective
Grilo, A. L., & Mantalaris, A. (2019) · Biotechnology Advances · doi:10.1016/j.biotechadv.2019.02.012 · Cited by 175
Oleic acid induces apoptosis and autophagy in the treatment of Tongue Squamous cell carcinomas
Jiang, L., Wang, W., He, Q., Wu, Y. Q., Lu, Z., Sun, J., Liu, Z., Shao, Y., & Wang, A. (2017) · Scientific Reports · doi:10.1038/s41598-017-11842-5 · Cited by 170
Why Senescent Cells Are Resistant to Apoptosis: An Insight for Senolytic Development
Hu, L., Li, H., Zi, M., Li, W., Liu, J., Yang, Y., Zhou, D., Kong, Q., Zhang, Y., & He, Y. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.822816 · Cited by 174
Knight, T. E., Luedtke, D. A., Edwards, H. J., Taub, J. W., & Ge, Y. (2019) · Biochemical Pharmacology · doi:10.1016/j.bcp.2019.01.015 · Cited by 170
Al‐Sawaf, O., Robrecht, S., Zhang, C., Olivieri, S., Chang, Y. M., Fink, A., Tausch, E., Schneider, C., Ritgen, M., Kreuzer, K., et al. (2024) · Blood · doi:10.1182/blood.2024024631 · Cited by 174
BCL2: A promising cancer therapeutic target
Radha, G., & Raghavan, S. C. (2017) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2017.06.004 · Cited by 165
Targeting oncogene and non-oncogene addiction to inflame the tumour microenvironment
Petroni, G., Buqué, A., Coussens, L. M., & Galluzzi, L. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00415-5 · Cited by 162
The rise of apoptosis: targeting apoptosis in hematologic malignancies
Valentin, R., Grabow, S., & Davids, M. S. (2018) · Blood · doi:10.1182/blood-2018-02-791350 · Cited by 163
Development of a BCL-xL and BCL-2 dual degrader with improved anti-leukemic activity,
Lv, D., Pal, P., Liu, X., Jia, Y., Thummuri, D., Zhang, P., Hu, W., Pei, J., Zhang, Q., Zhou, S., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-27210-x · Cited by 158
Targeting the Bcl-2 Family in B Cell Lymphoma
Adams, C. M., Clark-Garvey, S., Porcu, P., & Eischen, C. M. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2018.00636 · Cited by 163
Protein–Small Molecule Interactions in Native Mass Spectrometry
Bennett, J. L., Nguyen, G. T. H., & Donald, W. A. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.1c00293 · Cited by 161
Meng, M., Huo, R., Wang, Y., Ma, N., Shi, X., Shen, X., & Chang, G. (2022) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2022.10.024 · Cited by 155
Rational Design of Peptide-Based Inhibitors Disrupting Protein-Protein Interactions
Wang, X., Ni, D., Liu, Y., & Lu, S. (2021) · Frontiers in Chemistry · doi:10.3389/fchem.2021.682675 · Cited by 162
MDM2 Inhibitors for Cancer Therapy: The Past, Present, and Future
Wang, W., Albadari, N. G., Du, Y., Fowler, J. F., Sang, H. T., Xian, W., McKeon, F., Li, W., Zhou, J., & Zhang, R. (2024) · Pharmacological Reviews · doi:10.1124/pharmrev.123.001026 · Cited by 151
Deubiquitinase USP13 dictates MCL1 stability and sensitivity to BH3 mimetic inhibitors
Zhang, S., Zhang, M., Jing, Y., Yin, X., Ma, P., Zhang, Z., Wang, X., Di, W. J., & Zhuang, G. (2018) · Nature Communications · doi:10.1038/s41467-017-02693-9 · Cited by 150
Liao, M., Qin, R., Huang, W., Zhu, H.-P., Peng, F., Han, B., & Liu, B. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01260-0 · Cited by 149
Post-Transcriptional Regulation of Anti-Apoptotic BCL2 Family Members
Cui, J., & Placzek, W. J. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19010308 · Cited by 142
Fiskus, W. C., Boettcher, S., Daver, N. G., Mill, C. P., Sasaki, K., Birdwell, C. E., Davis, J. A., Takahashi, K., Kadia, T. M., Dinardo, C. D., et al. (2022) · Blood Cancer Journal · doi:10.1038/s41408-021-00603-3 · Cited by 139
Winer, H. Y., Rodrigues, G. O. L., Hixon, J. A., Aiello, F. B., Hsu, T. C., Wachter, B. T., Li, W., & Durum, S. K. (2022) · Cytokine · doi:10.1016/j.cyto.2022.156049 · Cited by 136
BCL-2 family deregulation in colorectal cancer: potential for BH3 mimetics in therapy
Ramesh, P., & Medema, J. P. (2020) · APOPTOSIS · doi:10.1007/s10495-020-01601-9 · Cited by 134
Cummings, M. D., & Sekharan, S. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01985 · Cited by 134
Influenza Virus Infection, Interferon Response, Viral Counter-Response, and Apoptosis
Shim, J. M., Kim, J., Tenson, T., Min, J.-Y., & Kainov, D. E. (2017) · Viruses · doi:10.3390/v9080223 · Cited by 133
Current NMR Techniques for Structure-Based Drug Discovery
Sugiki, T., Furuita, K., Fujiwara, T., & Kojima, C. (2018) · Molecules · doi:10.3390/molecules23010148 · Cited by 134
Leverson, J. D., Sampath, D., Souers, A. J., Rosenberg, S. H., Fairbrother, W. J., Amiot, M., Konopleva, M. Y., & Letai, A. G. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0797 · Cited by 126
Self-citationSenescence drives immunotherapy resistance by inducing an immunosuppressive tumor microenvironment
Maggiorani, D., Lê, O., Lisi, V., Landais, S., Moquin‐Beaudry, G., Lavallée, V., Decaluwe, H., & Beausejour, C. M. (2024) · Nature Communications · doi:10.1038/s41467-024-46769-9 · Cited by 130
Li, L., Wang, S., & Zhou, W. (2022) · Cancers · doi:10.3390/cancers15010026 · Cited by 126
Casara, P., Davidson, J. E. P., Clapéron, A., Toumelin-Braizat, G. L., Vogler, M., Bruno, A., Chanrion, M., Lysiak-Auvity, G., Diguarher, T. L., Starck, J.-B., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.24744 · Cited by 119
Combination therapy based on nano codelivery for overcoming cancer drug resistance
Wang, H., & Huang, Y. (2020) · Medicine in Drug Discovery · doi:10.1016/j.medidd.2020.100024 · Cited by 115
Chen, Z., Li, W., Santhanam, R. K., Wang, C., Gao, X., Chen, Y., Wang, C., Xu, L., & Chen, H. (2018) · European Food Research and Technology · doi:10.1007/s00217-018-3190-5 · Cited by 112
Zhang, Q., Peng, W., Wei, S., Wei, D., Li, R., Liu, J., Peng, L., Yang, S., Gao, Y., Wu, C., et al. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.109367 · Cited by 111
Targeting mitochondria as an anticancer strategy
Dong, L., & Neužil, J. (2019) · 癌症：英文版 · doi:10.1186/s40880-019-0412-6 · Cited by 111
Puerarin: a potential natural neuroprotective agent for neurological disorders
Liu, X., Huang, R., & Wan, J. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114581 · Cited by 111
PROTACs: Emerging Targeted Protein Degradation Approaches for Advanced Druggable Strategies
Sincere, N. I., Anand, K., Ashique, S., Yang, J., & You, C. (2023) · Molecules · doi:10.3390/molecules28104014 · Cited by 112
Saddam, M., Paul, S. K., Habib, M. A., Fahim, M. A., Mimi, A. A., Islam, S., Paul, B., & Helal, M. M. U. (2024) · Egyptian Journal of Medical Human Genetics · doi:10.1186/s43042-024-00485-7 · Cited by 110
Advances in the study of emodin: an update on pharmacological properties and mechanistic basis
Zheng, Q., Li, S., Li, X., & Liu, R. (2021) · Chinese Medicine · doi:10.1186/s13020-021-00509-z · Cited by 106
Small-molecule allosteric inhibitors of BAX
Garner, T. P., Amgalan, D., Reyna, D. E., Li, S., Kitsis, R. N., & Gavathiotis, E. (2019) · Nature Chemical Biology · doi:10.1038/s41589-018-0223-0 · Cited by 105
Cellular senescence and radiation-induced pulmonary fibrosis
He, Y., Thummuri, D., Zheng, G., Okunieff, P. G., Citrin, D. E., Vujašković, Ž., & Zhou, D. (2019) · Translational research · doi:10.1016/j.trsl.2019.03.006 · Cited by 107
Chemopreventive effects of some popular phytochemicals on human colon cancer: a review
Zhao, Y., Hu, X., Zuo, X., & Wang, M. (2018) · Food & Function · doi:10.1039/c8fo00850g · Cited by 104
Bcl-XL: A multifunctional anti-apoptotic protein
Li, M., Wang, D., He, J., Chen, L., & Li, H. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104547 · Cited by 109
Song, X., Huang, Q., Yang, Y., Ma, L., Liu, W., Ou, C., Chen, Q., Zhao, T., Xiao, Z., Wang, M., et al. (2023) · Advanced Materials · doi:10.1002/adma.202301585 · Cited by 103
Long noncoding RNA FTX regulates cardiomyocyte apoptosis by targeting miR-29b-1-5p and Bcl2l2
Long, B., Li, N., Xu, X., Li, X., Xu, X., Guo, D., Zhang, D., Wu, Z., & Zhang, S. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.11.030 · Cited by 102
BH3-mimetics: recent developments in cancer therapy
Townsend, P. A., Kozhevnikova, M. V., Cexus, O., Zamyatnin, A. A., & Soond, S. M. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02157-5 · Cited by 109
Rapidly inducible Cas9 and DSB-ddPCR to probe editing kinetics
Rose, J. C., Stephany, J. J., Valente, W. J., Trevillian, B. M., Dang, H. V., Bielas, J. H., Maly, D. J., & Fowler, D. M. (2017) · Nature Methods · doi:10.1038/nmeth.4368 · Cited by 101
Guo, Z., Liu, Y., Chen, D., Sun, Y., Li, D., Meng, Y., Zhou, Q., Zeng, F., Deng, G., & Chen, X. (2025) · Journal of Translational Internal Medicine · doi:10.1515/jtim-2025-0004 · Cited by 111
Al‐Sawaf, O., Zhang, C., Jin, H. Y., Robrecht, S., Choi, Y., Balasubramanian, S., Kotak, A., Chang, Y. M., Fink, A. M., Tausch, E., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-37648-w · Cited by 105
Antisense STAT3 inhibitor decreases viability of myelodysplastic and leukemic stem cells
Shastri, A., Choudhary, G. S., Teixeira, M., Gordon-Mitchell, S., Ramachandra, N., Bernard, L., Bhattacharyya, S., Lopez, R., Pradhan, K., Giricz, O., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci120156 · Cited by 95
Current overview on the clinical update of Bcl-2 anti-apoptotic inhibitors for cancer therapy
Suvarna, V., Singh, V., & Murahari, M. (2019) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2019.172655 · Cited by 89
Iwaloye, O., Ottu, P. O., Olawale, F., Babalola, O. O., Elekofehinti, O. O., Kikiowo, B., Adegboyega, A. E., Ogbonna, H. N., Adeboboye, C. F., Folorunso, I. M., et al. (2023) · Informatics in Medicine Unlocked · doi:10.1016/j.imu.2023.101332 · Cited by 90
A matter of life and death: stem cell survival in tissue regeneration and tumour formation
Soteriou, D., & Fuchs, Y. (2018) · Nature Reviews Cancer · doi:10.1038/nrc.2017.122 · Cited by 87
Wu, X., Luo, Q., & Liu, Z. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-02760-y · Cited by 91
Bioactive Compounds from Mangrove Endophytic Fungus and Their Uses for Microorganism Control
Cadamuro, R. D., Bastos, I. M. A. D. S., Silva, I. T., da Cruz, A. C. C., Robl, D., Sandjo, L. P., Júnior, S. L. A., Lorenzo, J. M., Rodrı́guez-Làzaro, D., Treichel, H., et al. (2021) · Journal of Fungi · doi:10.3390/jof7060455 · Cited by 87
Targeting mitochondria for cancer photodynamic therapy
Yaqoob, M. D., Xu, L., Li, C., Leong, M. M., & Xu, D. (2022) · Photodiagnosis and Photodynamic Therapy · doi:10.1016/j.pdpdt.2022.102830 · Cited by 89
The role of E3 ubiquitin ligases in the development and progression of glioblastoma
Humphreys, L. M., Smith, P., Chen, Z., Fouad, S., & D’Angiolella, V. (2021) · Cell Death and Differentiation · doi:10.1038/s41418-020-00696-6 · Cited by 87
Progress in understanding the mechanisms of resistance to BCL-2 inhibitors
Xu, Y., & Ye, H. (2022) · Experimental Hematology and Oncology · doi:10.1186/s40164-022-00283-0 · Cited by 87
Current senolytics: Mode of action, efficacy and limitations, and their future
Rad, A. N., & Grillari, J. (2023) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2023.111888 · Cited by 87
Small molecules as inhibitors of PCSK9: Current status and future challenges
Xu, S., Luo, S., Zhu, Z., & Xu, J. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.11.011 · Cited by 85
Li, C., Deng, C., Pan, G., Wang, X., Zhang, K., Dong, Z., Zhao, G., Tan, M., Hu, X., Shi, S., et al. (2020) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01743-3 · Cited by 84
Proteomic discovery of chemical probes that perturb protein complexes in human cells
Lazear, M. R., Remsberg, J. R., Jaeger, M. G., Rothamel, K. L., Her, H.-L., DeMeester, K. E., Njomen, E., Hogg, S. J., Rahman, J. A., Whitby, L. R., et al. (2023) · Molecular Cell · doi:10.1016/j.molcel.2023.03.026 · Cited by 85
Regulation of Apoptosis during Flavivirus Infection
Okamoto, T., Suzuki, T., Kusakabe, S., Tokunaga, M., Hirano, J., Miyata, Y., & Matsuura, Y. (2017) · Viruses · doi:10.3390/v9090243 · Cited by 83
Targeting apoptosis in acute myeloid leukaemia
Cassier, P. A., Castets, M., Belhabri, A., & Vey, N. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.281 · Cited by 86
Wang, P., Yang, H., Liu, C., Qiu, M., Ma, X., Mao, Z., Sun, Y., & Liu, Z. (2020) · Chinese Chemical Letters · doi:10.1016/j.cclet.2020.11.056 · Cited by 81
Peptidomimetics: A Synthetic Tool for Inhibiting Protein–Protein Interactions in Cancer
Mabonga, L., & Kappo, A. P. (2019) · International Journal of Peptide Research and Therapeutics · doi:10.1007/s10989-019-09831-5 · Cited by 81
Phillips, D. C., Jin, S. S., Gregory, G. P., Zhang, Q., Xue, J., Zhao, X., Chen, J., Tong, Y., Zhang, H., Smith, M. L., et al. (2019) · Leukemia · doi:10.1038/s41375-019-0652-0 · Cited by 78
Self-citationFresquet, V., Garcia-Barchino, M. J., Larráyoz, M., Celay, J., Vicente, C., Fernández‐Galilea, M., Larráyoz, M. J., Calasanz, M. J., Panizo, C., Junza, A., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1065 · Cited by 77
Aging and Mesenchymal Stem Cells: Basic Concepts, Challenges and Strategies
Fraile, M., Eiró, N., Costa, L. A., Martín, A., & Vizoso, F. J. (2022) · Biology · doi:10.3390/biology11111678 · Cited by 79
Aird, D. R., Teng, T., Huang, C. L., Pazolli, E., Banka, D., Cheung-Ong, K., Eifert, C., Furman, C., Wu, Z. J., Seiler, M., et al. (2019) · Nature Communications · doi:10.1038/s41467-018-08150-5 · Cited by 78
Zhao, L., Liu, P., Mao, M., Zhang, S., Bigenwald, C., Dutertre, C., Lehmann, C. H. K., Pan, H., Paulhan, N., Amon, L., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-1338 · Cited by 77
The third model of Bax/Bak activation: a Bcl-2 family feud finally resolved?
Luo, X., O’Neill, K. L., & Huang, K. (2020) · F1000Research · doi:10.12688/f1000research.25607.1 · Cited by 77
Wang, X.-M., Liu, X., Wang, Y., & Chen, Z.-Y. (2020) · Bioengineered · doi:10.1080/21655979.2020.1860491 · Cited by 74
Current Advances and Future Strategies for BCL-2 Inhibitors: Potent Weapons against Cancers
Xu, J., Dong, X., Huang, D. C. S., Xu, P., Zhao, Q., & Chen, B. (2023) · Cancers · doi:10.3390/cancers15204957 · Cited by 75
Wu, X., Luo, Q., Zhao, P., Chang, W., Wang, Y., Shu, T., Ding, F., Li, B., & Liu, Z. (2019) · Cell Death and Differentiation · doi:10.1038/s41418-019-0339-0 · Cited by 76
Lunov, O., Uzhytchak, M., Smolková, B., Lunová, M., Jirsa, M., Dempsey, N. M., Dias, A., Bonfim, M. J. C., Hof, M., Jurkiewicz, P., et al. (2019) · Cancers · doi:10.3390/cancers11121873 · Cited by 75
Wang, J., Li, Z., Yang, W.-X., & Tan, F.-Q. (2022) · Reproductive Biology and Endocrinology · doi:10.1186/s12958-022-00971-w · Cited by 73
Sale, M. J., Minihane, E., Monks, N. R., Gilley, R., Richards, F. M., Schifferli, K. P., Andersen, C. L., Davies, E. J., Vicente, M. A., Ozono, E., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12409-w · Cited by 75
Pan, T., Fu, W. B., Xin, H., Geng, S., Li, Z., Cui, H., Zhang, Y. L., Chu, P. K.-H., Zhou, W., & Yu, X. (2020) · Advanced Functional Materials · doi:10.1002/adfm.202003069 · Cited by 72
Small molecules targeting protein–protein interactions for cancer therapy
Wu, D., Li, Y., Zheng, L., Xiao, H., Ouyang, L., Wang, G., & Sun, Q. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.05.035 · Cited by 71
Selective targeting of antiapoptotic BCL‐2 proteins in cancer
Timuçin, A. C., Başağa, H., & Kütük, Ö. (2018) · Medicinal Research Reviews · doi:10.1002/med.21516 · Cited by 73
Metadata
- Authors
- Ashkenazi, A., Fairbrother, W. J., Leverson, J. D., & Souers, A. J.
- Affiliations
- Genentech (US)
- AbbVie (United States) (US)
- Corresponding author
- Ashkenazi, Avi
- Venue
- Nature Reviews Drug Discovery
- Published
- 2017-02-17
- Volume
- 16
- Issue
- 4
- Pages
- 273-284
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2589060305
- Cited by
- 903
- References
- 105
- Citations by year
- 2026: 49 · 2025: 87 · 2024: 99 · 2023: 90 · 2022: 94 · 2021: 120 · 2020: 116 · 2019: 93 · 2018: 100 · 2017: 51
- FWCI
- 9.25
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Keywords
- Bcl-2 family proteins, apoptosis, BH3 mimetics, BCL-2 inhibitor, venetoclax, navitoclax, Bcl-xL, Mcl-1, small molecule inhibitors, structure-based drug design, NMR-based screening, apoptosis evasion, chronic lymphocytic leukemia, 17p deletion, cancer therapy
- MeSH terms
- Antineoplastic Agents, Humans, Neoplasms, Molecular Structure, Apoptosis, Proto-Oncogene Proteins c-bcl-2, Protein Interaction Domains and Motifs, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
